Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response

Cancer Research

Volumn 61, Issue 22, 2001, Pages 8227-8234

  Parajuli, Prahlad ^a   Pisarev, Vladimir ^b   Sublet, Jennifer ^b   Steffel, Amy ^b   Varney, Michelle ^b   Singh, Rakesh ^b   Laface, Drake ^c   Talmadge, James E ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; FEMALE; GENE THERAPY; IMMUNE RESPONSE; IMMUNIZATION; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TUMOR IMMUNITY;

ADENOVIRIDAE; ANIMALS; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; FEMALE; GENES, P53; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNIZATION; INTERFERON TYPE II; INTERLEUKINS; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MUTATION; PLASMIDS; SPLEEN; T-LYMPHOCYTES;

EID: 0035890587     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Cancer. A deadly inheritance
2. p53 mutations in human cancers
3. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract
4. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas
5. Targeting p53 as a general tumor antigen
6. p53, a potential target for tumor-directed T cells
7. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide
8. Induction of Th1 and Th2 CD4+ T cell responses: The alternative approaches
9. CD8α+ and CD8α-subclasses of dendritic cells direct the development of distinct T helper cells in vivo
10. Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response
11. Cancer vaccines
12. Dendritic cells as adjuvants for immune-mediated resistance to tumors
13. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases
14. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity
15. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
16. DNA vaccines targeting dendritic cells for the immunotherapy of cancer
17. Generating a T cell tumor-specific immune response in vivo: Can flt3-ligand-generated dendritic cells tip the balance?
18. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified
19. Induction of dendritic cells (DC) by Flt3 Ligand (FL) promotes the generation of tumor-specific immune responses in vivo
20. Flt3 ligand induces tumor regression and antitumor immune responses in vivo
21. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo
22. Development and characterization of recombinant adenovirus encoding human p53 for gene therapy of cancer
23. Recombinant El-deleted adenovirus-mediated gene therapy for cancer: Efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models
24. Gene therapy for non-small cell lung cancer: A preliminary report of a Phase I trial of adenoviral p53 gene replacement
25. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
26. Viral and nonviral gene delivery vectors for cancer gene therapy
27. Suppression of human colorectal carcinoma cell growth by wild-type p53
28. Adenovirus p53 purging for human breast cancer stem cell products
29. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor
30. Heterogeneity in p53 mutations in mouse mammary tumor subpopulations with different metastatic potential from the orthotopic site
31. Association of alterations in structure and expression of c-Ha-ras, p53, and nm23 with metastatic potential in an orthotopic mammary cancer model
32. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: Heterogeneity in phenotypic stability
33. Sequence motifs important for peptide binding to the human MHC class 1 molecule, HLA-A2
34. The effect of pentoxyfilline (PTX) on Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease
35. Concurrent production of interleukin-2, interleukin-10, and γ-interferon in the regional lymph nodes of mice with influenza pneumonia
36. Immune mechanisms in homotransplantation. II. Quantitative assay of the immunological activity of lymphoid cells stimulated by tumor homografts
37. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines
38. Cross-presentation, dendritic cells, tolerance and immunity
39. Genetic vaccines
40. Modulating the immune response to genetic immunization
41. DNA vaccination: Transfection and activation of dendritic cells as key events for immunity
42. Flt3 ligand administration inhibits tumor growth in murine melanoma and lymphoma
43. Flt3 ligand antitumor activity in a murine breast cancer model: A comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action
44. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model
45. IL-12 and mutant P53 peptide-pulsed dendritic cel]s for the specific immunotherapy of cancer
46. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma
47. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: Studies with the model tumor antigen β-galactosidase and the BALB/c Meth A p53 tumor-specific antigen
48. Cytotoxic T cell responses to DNA vaccination: Dependence on antigen presentation via class II MHC